• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists kill cancer cells by ‘shutting the door’ to the nucleus

Bioengineer by Bioengineer
September 28, 2020
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Proof-of-concept study shows that stopping the construction of nuclear pore complexes selectively kills cancer cells

IMAGE

Credit: Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that blocking the construction of nuclear pores complexes–large channels that control the flow of materials in and out of the cell nucleus–shrank aggressive tumors in mice while leaving healthy cells unharmed. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research, reveals a new Achilles heel for cancer that may lead to better treatments for deadly tumors such as melanoma, leukemia and colorectal cancer.

“Nuclear pore complexes are the ‘doors’ that all materials pass through to gain entry to the cell’s nucleus. Because cancer cells are rapidly growing and dividing they need and create more nuclear pore complexes than normal cells,” says Maximiliano D’Angelo, Ph.D., associate professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys. “Our study is the first to demonstrate that by blocking the formation of these nuclear ‘doors’ we can selectively kill cancer cells.”

A promising new way to treat cancer

Because cancer cells are highly dependent on the nuclear transport process–the movement of molecules through nuclear pores–targeting the nuclear transport machinery is a promising strategy for cancer therapies. D’Angelo is hopeful that targeting the formation of nuclear pore complexes, which only impacts dividing cells and thus would likely only kill cancer cells, may offer a safe way to treat many cancer types. However, until now this hypothesis had not yet been tested.

In the study, D’Angelo and his team tested this hypothesis by transplanting human tumor cells that are unable to form nuclear pore complexes into mice. Three different tumor cell types were tested–melanoma, leukemia and colorectal cancer–which are known to be especially reliant on nuclear pore complexes. The scientists found that all of these mice had smaller tumors and slower tumor growth.

“We showed that the inability to build nuclear pore channels is devastating for rapidly-growing cancer cells, but doesn’t seem to have an impact on healthy cells–which simply halt their growth, and then recover,” says Stephen Sakuma, a graduate student in the D’Angelo lab and first author of the study. “Our findings provide an important proof of concept that this approach could lead to a new type of cancer treatment, which might be especially beneficial for aggressive or metastatic cancers that are difficult to treat.”

From discovery to drug

Now that the scientists have demonstrated that their approach works, they are working to find a drug that can block the formation of nuclear pore complexes. This work is ongoing at the Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys, one of the most advanced drug discovery centers in the nonprofit world.

“In addition to one day helping people with tough-to-treat cancers, we envision this drug candidate might be used to prevent drug resistance, which happens when tumors adopt properties to resist therapy,” says D’Angelo. “Tumors would have a hard time adopting to an environment where their ‘doors’ are removed, so this drug might help certain treatments, such as targeted therapies, remain effective for longer periods of time.”

###

Additional study authors include Marcela Raices, Joana Borlido, Valeria Guglielmi and Ethan Y.S. Zhu of Sanford Burnham Prebys. The study’s DOI is 10.1158/2159-8290.CD-20-0581.

This work was supported by the National Institutes of Health (RO1AR065083, RO1AR065083-S1, R01AI148668, P30CA030199) and the American Cancer Society (RSG-17-148-01-CCG).

About Sanford Burnham Prebys Medical Research Institute

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

Media Contact
Susan Gammon
[email protected]

Related Journal Article

http://dx.doi.org/10.1158/2159-8290.CD-20-0581

Tags: BiologycancerCell Biology
Share13Tweet8Share2ShareShareShare2

Related Posts

Medicaid Innovation Models Enhance Maternal Care, Highlighting the Importance of Strategic Design

October 8, 2025

AI Mimics Pathologists for Clear Prostate Cancer Grading

October 8, 2025

Dual HDAC/PI3K Inhibitors Trigger Apoptosis in p53-Mutant Lymphoma

October 8, 2025

Sickle Cell Disease Patients Experience Significant Delays in Emergency Department Pain Management

October 8, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1098 shares
    Share 438 Tweet 274
  • New Study Reveals the Science Behind Exercise and Weight Loss

    100 shares
    Share 40 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    95 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    79 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Scientists Develop Radiotheranostic Strategy to Target Aggressive Cancers

Harnessing Alcohol Dehydrogenases for Sustainable Amide and Thioester Synthesis

How Smoking and Biological Sex Influence Healthy Bladder Tissue Development: New Insights into Cancer Risk

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.